Our Therapies
Therapies in Development
From our history of innovation to our future-forward approach to therapeutic advancements, we are committed to uncovering new treatments to transform patients’ lives. Our pipeline highlights a portfolio of investigational therapies in varied stages of clinical development. Advancing global health care through innovation.
Therapeutic Area
Candidate
Indication/Target
Phase
Therapeutic Area
Indication/Target
Candidate
Schizophrenia
Ulotaront
(SEP-363856)
Phase 3 75% complete
Adjunctive major depressive disorder
Ulotaront
(SEP-363856)
Phase 3 75% complete
Generalized anxiety disorder
Ulotaront
(SEP-363856)
Phase 3 75% complete
Bipolar Depression
SEP-4199
Phase 3 75% complete
Parkinson’s disease psychosis
Ulotaront
(SEP-363856)
Phase 2 50% complete
Neuropathic pain
DSP-3905
Phase 1 25% complete
Bipolar Depression
Phase 1 25% complete
Treatment-resistant depression
SEP-378614
Phase 1 25% complete
Agitation in Alzheimer’s disease
SEP-380135
Phase 1 25% complete
Alzheimer’s disease psychosis
DSP-0038
Phase 1 25% complete
Treatment-resistant depression
DSP-3456
Phase 1 25% complete
To be determined
DSP-2342
Phase 1 25% complete